Drugs / 2,2'-DITHIODIETHANESULFONIC ACID

Trials 2 · a red edge is where a trial was stopped

200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 2 NCT05456256 Mar 2023 → Dec 2026 expected lung adenocarcinoma Lantern Pharma Inc. Recruiting No outcome recorded
Phase 2 NCT00077311 Aug 2004 → Jul 2006 anemia, chemotherapy-induced toxicity, lung cancer, neutropenia Alliance for Clinical Trials in Oncology Completed No outcome recorded
Also used as a comparator or background therapy in 2 trials
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 3 NCT00966914 Comparator Apr 2010 → Apr 2013 non-small cell lung carcinoma BioNumerik Pharmaceuticals, Inc. Completed No outcome recorded
Phase 3 NCT00039780 Comparator Sep 2001 → Oct 2006 breast cancer, metastatic malignant neoplasm BioNumerik Pharmaceuticals, Inc. Completed No outcome recorded

Evidence & citations 10 cited values

Every value below carries the sentence it was read from. 5 sources stand behind the page.

FieldValueCited text
Known as 2,2'-DITHIODIETHANESULFONIC ACID ChEMBL registry synonym — accepted as the source's own label CHEMBL2009034
Known as BNP7787 ClinicalTrials.gov intervention name — accepted as the source's own label NCT00077311
1

NCT00039780

Known as BNP7787 also known as Tavocept BNP7787 also known as TavoceptNCT00039780
Known as DIMESNA ChEMBL registry synonym — accepted as the source's own label CHEMBL2009034
Known as LP-300 ClinicalTrials.gov intervention name — accepted as the source's own label NCT05456256
Known as NSC-716976 ChEMBL registry synonym — accepted as the source's own label CHEMBL2009034
Known as NSC-760345 ChEMBL registry synonym — accepted as the source's own label CHEMBL2009034
Known as Tavocept ClinicalTrials.gov intervention name — accepted as the source's own label NCT00966914
Modality Small molecule CHEMBL2009034
Route Intravenous “40 g IV over 30 min Day 1 of each cycle” NCT00077311